ArticleBasic and clinical neuroscience2025
Statistical Method for Identification of Alzheimer Disease With Multimodal Predictive Markers Mild Cognitive Impairment.
Article in Basic and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explainable hierarchical machine-learning approaches for multimodal prediction of conversion from mild cognitive impairment to Alzheimer's disease.Physical and engineering sciences in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) is crucial for early intervention. Identifying reliable predictive markers can enhance diagnostic accuracy and improve clinical decision-making. This study aimed to explore multimodal predictive markers to distinguish stable MCI (sMCI) from progressive MCI (pMCI) to AD using statistical analysis. Methods: We analyzed data from the Alzheimer's disease neuroimaging initiative (ADNI), categorizing 487 individuals as sMCI and 348 as pMCI. The study incorporated multiple assessment modalities, including demographics, positron emission tomography (PET), genotyping, magnetic resonance imaging (MRI), and neurocognitive tests. A rigorous data preprocessing approach was applied, including cleaning and feature selection. The area under the curve (AUC) and the Wilcoxon test were used to evaluate the discriminative power of predictive markers. Results: Our findings showed the strong predictive potential of PET, particularly florbetaben (FBB), which achieved an AUC of 0.84. Neurocognitive tests, including the Alzheimer's disease assessment scale (ADAS13), ADNI-modified preclinical Alzheimer cognitive composite (mPACCtrailsB and mPACCdigit), logical memory delayed recall total (LDELTOTAL), and ADAS cognitive subscale question 4 (ADASQ4), also demonstrated high discriminatory power with AUC values ranging from 0.82 to 0.83. These results indicated that a combination of neuroimaging and cognitive assessments can significantly differentiate between sMCI and pMCI. Conclusion: The results emphasize the importance of multimodal assessments, particularly PET imaging and neurocognitive tests, in distinguishing sMCI from pMCI. These findings contribute to early AD diagnosis strategies and personalized intervention planning..
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.